Boston Scientific Corp (BSX) reports impressive Q4 2024 results with 22.4% revenue growth and a 26% increase in adjusted EPS, ...

Boston Scientific is reaping the rewards from the energised PFA market opportunity in atrial fibrillation treatment.

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same ...

Boston Scientific Corporation (BSX), a medical technology company, Wednesday reported net income of $566 million or $0.38 per share ...

Stifel raised the firm’s price target on Boston Scientific (BSX) to $120 from $115 and keeps a Buy rating on the shares after having hosted ...

Boston Scientific Corporation ( NYSE: BSX) Q4 2024 Earnings Conference Call February 5, 2025 8:00 AM ET Jonathan Monson - SVP, IR Michael Mahoney - Chairman and CEO Daniel Brennan - EVP and CFO ...

Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...

For the current quarter ending in March, Boston Scientific expects its per-share earnings to range from 66 cents to 68 cents. The company expects full-year earnings in the range of $2.80 to $2.87 per ...

Boston Scientific Q4 revenue rose 22.4% Y/Y to $4.56B, exceeding the $4.424B consensus. Adjusted EPS of $0.70 beat expectations of $0.66. Cardiovascular sales grew 28.8% to $2.94B, with cardiology ...

(RTTNews) - Boston Scientific Corporation (BSX), a medical technology company, Wednesday reported net income of $566 million or $0.38 per share for the fourth quarter, higher than $504 million or ...